Assessment of the effect of nano-curcumin oral intake on clinical signs and serum IL-6 levels in patients with ischemic stroke: Double-blind Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091108002680N3

Enrollment

Registered

2020-02-24

Start date

2020-04-20

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic cerebral stroke. Stroke, non specified as haemorrhage or infarction

Interventions

Intervention 1: Intervention group: capsule nano-curcumin (sina curcumin) 80 mg Daily for 1 month. Intervention 2: Control group: Capsules containing polycarbate 80 are quite similar to the main drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ischemic CVA less than 1 week from their symptoms begin National Institutes of Health Stroke Scale (NIHSS) <= 20 Modified Rankin Scale (MRS) <= 4

Exclusion criteria

Exclusion criteria: Cerebral Venous Thrombosis Hemorrhagic infarction Internal capsule and Middle Cerebral Artery trunk infarction History of gall bladder stone or bile duct stenosis Gastroesophageal reflux disease or active peptic ulcer Use of NSAIDs or Reserpine Using anticoagulant or thrombolitic agent in last 24 hours Using of Warfarin in last 1 week Dissatisfaction More than 1 week from symptoms begin

Design outcomes

Primary

Measure	Time frame
Blood levels of inflammatory factor interleukin-6. Timepoint: Before treatment and after 1 month. Method of measurement: ELISA kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Alia Saberi

Rasht University of Medical Sciences

a_saberi@gums.ac.ir+98 13 3332 2444

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026